Pure Global
NCT06315257

A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

A Randomized, Open-label Clinical Trial to Assess the Safety, Feasibility and Immunogenicity of Adjuvant PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cervical Cancer
Drug/Device/Intervention
PVX7
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Timeline & enrollment
Phase
Phase 1
Start date
Aug 01, 2024
End date
Mar 01, 2027
Enrollment
32 participants
Primary outcome

Safety of PVX7 as assessed by adverse events,Feasibility of PVX7

Summary

A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed
 primary definitive therapy.

ICD-10 classifications
Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06315257
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06315257 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is currently Not yet recruiting. The study focuses on Cervical Cancer. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.